XLO Xilio Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1840233 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY73.0%
TTM net income YoY80.4%
TTM EPS YoY103.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-74.9%
Net margin-20.9%
FCF margin-104.8%
EBITDA margin-72.6%
Returns
ROE-38.2%
ROA-8.6%
ROIC (approx.)—
Asset turnover0.41x
Leverage & solvency
Liabilities / assets49.4%
Debt / equity0.00x
Current ratio4.72x
Interest coverage—
Cash quality & payout
Operating cash flow / net income4.95x
Accruals ratio33.8%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $9.98M | $18.69M | $12.65M | $13.69M | $19.07M | $8.08M | $2.93M | $1.72M |
| R&D expense | $14.80M | $14.56M | $19.83M | $18.12M | $14.32M | $15.33M | $8.27M | $8.84M |
| SG&A expense | $6.93M | $7.62M | $6.93M | $7.40M | $6.67M | $7.12M | $8.52M | $6.52M |
| Operating income | -$11.75M | -$3.49M | -$14.11M | -$11.84M | -$1.93M | -$14.37M | -$13.85M | -$13.63M |
| Net income | -$5.95M | -$6.37M | -$9.53M | $10.36M | -$16.29M | -$15.84M | -$13.27M | -$13.09M |
| EBITDA | -$11.45M | -$3.19M | -$13.77M | -$11.51M | -$1.63M | -$13.97M | -$13.35M | -$13.25M |
| EPS (basic) | -0.30 | -0.33 | -0.58 | — | -1.58 | -2.30 | -2.49 | — |
| EPS (diluted) | -0.30 | -0.33 | -0.58 | — | -1.58 | -2.30 | -2.49 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $122.18M | $136.04M | $150.33M | $137.53M | $103.76M | $121.55M | $89.07M | $57.07M |
| Current assets | $126.50M | $145.47M | $154.21M | $145.03M | $124.09M | $123.72M | $93.20M | $60.23M |
| PP&E, net | $3.09M | $3.36M | $3.68M | $3.89M | $3.68M | $4.02M | $4.29M | $4.47M |
| Total assets | $134.83M | $154.25M | $163.49M | $154.69M | $133.69M | $133.81M | $103.72M | $71.08M |
| Current liabilities | $26.80M | $34.20M | $42.96M | $56.27M | $56.40M | $53.26M | $47.64M | $27.26M |
| Total liabilities | $66.60M | $81.99M | $90.94M | $119.41M | $141.79M | $126.74M | $93.02M | $53.48M |
| Shareholders' equity | $68.23M | $72.26M | $72.55M | $35.27M | -$8.10M | $7.07M | $10.70M | $17.60M |
| Shares outstanding | 6.59M | 6.58M | 5.78M | 4.53M | 51.83M | 51.83M | 51.78M | 3.27M |
| Cash flow statement | ||||||||
| Operating cash flow | -$13.79M | -$18.76M | -$22.34M | -$2.00M | -$17.50M | -$14.48M | $28.98M | -$14.16M |
| Capital expenditure | $58,000 | $19,000 | $556,000 | $95,000 | $0 | $401,000 | $22,000 | $6,000 |
| Free cash flow | -$13.85M | -$18.78M | -$22.90M | -$2.09M | -$17.50M | -$14.88M | $28.96M | -$14.16M |
| Investing cash flow | -$58,000 | -$19,000 | -$556,000 | -$95,000 | $0 | -$401,000 | -$22,000 | -$6,000 |
| Financing cash flow | $0 | $4.49M | $35.71M | $35.87M | -$285,000 | $47.36M | $4.83M | $8.20M |
| Depreciation & amortization | $300,000 | $300,000 | $344,000 | $323,000 | $300,000 | $400,000 | $497,000 | $376,000 |
| Stock-based compensation | $1.92M | $1.60M | $2.21M | $2.93M | $1.12M | $1.35M | $1.53M | $1.52M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.